Your browser doesn't support javascript.
loading
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Zemanick, Edith T; Taylor-Cousar, Jennifer L; Davies, Jane; Gibson, Ronald L; Mall, Marcus A; McKone, Edward F; McNally, Paul; Ramsey, Bonnie W; Rayment, Jonathan H; Rowe, Steven M; Tullis, Elizabeth; Ahluwalia, Neil; Chu, Chenghao; Ho, Thang; Moskowitz, Samuel M; Noel, Sabrina; Tian, Simon; Waltz, David; Weinstock, Tanya G; Xuan, Fengjuan; Wainwright, Claire E; McColley, Susanna A.
Afiliación
  • Zemanick ET; Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado.
  • Taylor-Cousar JL; Department of Medicine and.
  • Davies J; Department of Pediatrics, National Jewish Health, Denver, Colorado.
  • Gibson RL; National Heart and Lung Institute, Imperial College London, National Institute for Health Research Imperial Biomedical Research Centre and Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom.
  • Mall MA; University of Washington/Seattle Children's Hospital, Seattle, Washington.
  • McKone EF; Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • McNally P; Berlin Institute of Health, Berlin, Germany.
  • Ramsey BW; German Center for Lung Research, Berlin, Germany.
  • Rayment JH; St. Vincent's University Hospital and University College, Dublin, Ireland.
  • Rowe SM; Children's Health Ireland and Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland.
  • Tullis E; University of Washington/Seattle Children's Hospital, Seattle, Washington.
  • Ahluwalia N; British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
  • Chu C; University of Alabama at Birmingham, Birmingham, Alabama.
  • Ho T; St. Michael's Hospital, Toronto, Ontario, Canada.
  • Moskowitz SM; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • Noel S; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • Tian S; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • Waltz D; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • Weinstock TG; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • Xuan F; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • Wainwright CE; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
  • McColley SA; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Am J Respir Crit Care Med ; 203(12): 1522-1532, 2021 06 15.
Article en En | MEDLINE | ID: mdl-33734030
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Quinolonas / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Fibrosis Quística / Agonistas de los Canales de Cloruro / Indoles Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Child / Female / Humans / Male Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Quinolonas / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Fibrosis Quística / Agonistas de los Canales de Cloruro / Indoles Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Child / Female / Humans / Male Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2021 Tipo del documento: Article